Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

PharmGKB summary: very important pharmacogene information for CYP2B6.

Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB.

Pharmacogenet Genomics. 2010 Aug;20(8):520-3. No abstract available.

2.

CYP2B6: inching towards personalized medicine.

Gogtay NJ.

J Postgrad Med. 2012 Oct-Dec;58(4):233-4. doi: 10.4103/0022-3859.105436. No abstract available.

3.

Absence of CYP2B6 promoter -82T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections.

He ML, Lin C, Tong K, Xu B, Sung JJ, Kung HF, Lee SS.

Eur J Clin Pharmacol. 2006 Jul;62(7):585-6. Epub 2006 Jun 13. No abstract available.

PMID:
16770645
4.

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE.

Pharmacogenet Genomics. 2013 Dec;23(12):721-8. doi: 10.1097/FPC.0b013e3283653b27. Review. No abstract available.

5.

Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.

Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH.

Pharmacogenetics. 2004 Apr;14(4):225-38. Erratum in: Pharmacogenetics. 2005 Apr;15(4):265.

PMID:
15083067
6.

Detection of single nucleotide polymorphisms in CYP2B6 gene.

Zanger UM, Fischer J, Klein K, Lang T.

Methods Enzymol. 2002;357:45-53. No abstract available.

PMID:
12424896
7.

CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.

Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ.

Addict Biol. 2013 Jul;18(4):709-16. doi: 10.1111/j.1369-1600.2011.00349.x. Epub 2011 Jul 25.

8.

Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese.

Ariyoshi N, Iga Y, Hirata K, Sato Y, Miura G, Ishii I, Nagamori S, Kitada M.

Drug Metab Pharmacokinet. 2010;25(3):298-306.

9.

CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.

Mehlotra RK, Bockarie MJ, Zimmerman PA.

Br J Clin Pharmacol. 2007 Sep;64(3):391-5. Epub 2007 Mar 28.

10.

PXR polymorphisms interacted with CYP2B6 polymorphisms on methadone metabolites.

Tsai HJ, Wang SC, Tian JN, Chang TK, Ho IK, Hsiao CF, Chen CH, Tan HK, Lin L, Wu CS, Su LW, Huang CL, Yang YH, Liu ML, Lin KM, Liu YL.

J Clin Psychopharmacol. 2013 Feb;33(1):137-40. doi: 10.1097/01.jcp.0000426186.34421.de. No abstract available.

PMID:
23288240
11.

Slow efavirenz metabolism genotype is common in Botswana.

Gross R, Aplenc R, Tenhave T, Foulkes AS, Thakur R, Mosepele M, Barrett JS, Flexner C, Strom BL, Bisson G.

J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):336-7. doi: 10.1097/QAI.0b013e31817c1ed0. No abstract available.

12.

Pharmacogenetic screening: HLA-B(*) 5701 vs. CYP2B6 G516T.

Lin AW, Yam WC, Lam HY, To S, Chan D, Chan KC, Lee SS.

HIV Med. 2011 Apr;12(4):255-6. doi: 10.1111/j.1468-1293.2010.00870.x. No abstract available.

13.

The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status.

Helsby N, Tingle M.

Am J Hematol. 2011 Apr;86(4):383-4; author reply 384. doi: 10.1002/ajh.21987. No abstract available.

14.

PCR-based haplotype determination to distinguish CYP2B6*1/*7 and *5/*6.

Futatsugawa Y, Kubota T, Ishiguro A, Suzuki H, Ishikawa H, Iga T.

Clin Chem. 2004 Aug;50(8):1472-3. No abstract available.

15.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators.

J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29.

PMID:
21715435
16.

Cytochrome P450 2B6: function, genetics, and clinical relevance.

Turpeinen M, Zanger UM.

Drug Metabol Drug Interact. 2012;27(4):185-97. doi: 10.1515/dmdi-2012-0027. Review.

PMID:
23152403
17.

Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles.

Restrepo JG, Martínez C, García-Agúndez A, Gaviria E, Laguna JJ, García-Martín E, Agúndez JA.

Pharmacogenet Genomics. 2011 Dec;21(12):773-8. doi: 10.1097/FPC.0b013e32834b3efc.

PMID:
21886015
18.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25.

19.

Haplotypes frequencies of CYP2B6 in Malaysia.

Musa N, Zulkafli MI, Talib N, Mohamad N, Fauzi H, Ismail R.

J Postgrad Med. 2012 Oct-Dec;58(4):235-41. doi: 10.4103/0022-3859.105439.

20.

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW.

J Infect Dis. 2010 Sep 1;202(5):717-22. doi: 10.1086/655470.

Supplemental Content

Support Center